Related Experiment Video
Updated: May 20, 2026

Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction
Published on: May 17, 2024
Gynecomastia: a rare complication of isoretinoin?
Ihsan Ustun1, Emine Nur Rifaioglu, Bilge Bulbul Sen
1Department of Endocrinology, Mustafa Kemal University, Medical School of Medicine, Mustafa Kemal Universitesi Tıp Fakültesi Hastanesi, Serinyol, Antakya, Hatay, Turkey.
Abstract:
Isotretinoin is a retinoic acid derivative mostly used in the treatment of cystic acne vulgaris. The adverse effects of isotretinoin are well defined being the major limitation factor for its usage. The decrement of testosterone during isoretinoin treatment is defined in literature. We present a case with 20 years old man who developed gynecomastia after treatment with isotretinoin. To the best of our knowledge, this is the third report of the development of gynecomastia after isotretinoin treatment.
Insights
Isotretinoin, used for acne, may cause gynecomastia in men. This case report highlights a potential, though rare, adverse effect of this common acne medication.
Area of Science:
- Dermatology
- Endocrinology
Background:
- Isotretinoin is a vitamin A derivative widely prescribed for severe acne vulgaris.
- Known adverse effects of isotretinoin limit its clinical use.
- Testosterone level reduction during isotretinoin therapy is documented.
Related Concept Videos
Acne Infection
Cirrhosis I: Introduction
Disorders of the Female Reproductive System
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
